Evaluation of the diagnostic performance and its associated factors of a commercial anti-EV-A71 IgM-capture ELISA kit in hospitalized children with clinical diagnostic HFMD
Tianchen Zhang,Yibing Cheng,Yu Li,Junmei Yang,Lu Liang,Jianli Yang,Peng Cui,Chunlan Song,Yonghong Zhou,Di Kang,Qi Qiu,Ninghua Cui,Chun Guo,Yu Jing,Mengyao Zeng,Qianqian Liu,Lu Long,Chongchen Zhou,Hongjie Yu
DOI: https://doi.org/10.1016/j.jcv.2020.104582
IF: 14.481
2020-09-01
Journal of Clinical Virology
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Objectives</h3><p>Enterovirus A71 (EV-A71) is the main pathogen of severe hand, foot, and mouth disease (HFMD). Commercial enzyme-linked immunosorbent assays (ELISAs) are widely used in Chinese hospitals for the rapid diagnosis of acute EV-A71 infections. We present an evaluation of the diagnostic performance of a commercial anti-EV-A71 IgM-capture ELISA kit.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>A prospective, hospital-based HFMD cohort was established in Henan Children's Hospital (February 2017 - February 2018). Stool and blood specimens were collected from 1413 participants for diagnosing EVA71 by quantitative Real-Time Reverse Transcription-Polymerase Chain Reaction (qRT-PCR) and anti-EV-A71 ELISA.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>Detection yields of EV-A71 IgM increased from 6.5% (95% CI:3.3%-11.4%) at 0âž24âhours, to 42% (95% CI:28.3% -57.8) at 120âž144âhours from onset to sampling, and stabilized at âž40% after 144âhours. With increased time from onset to sampling, the sensitivity of the commercial ELISA increased from 0.54 (95% CI:0.25 - 0.81) to 0.74 (95% CI:0.43 - 0.66), while specificity decreased from 0.97 (95% CI:0.93 - 0.99) to 0.80 (95% CI:0.69 - 0.89), and PPV decreased from 0.96 (95% CI:0.92 - 0.99) to 0.84 (95% CI:0.73 - 0.92). Multivariate analysis found age, EV-A71 vaccination, previous HFMD/Herpangina infection, disease severity, infection during peak EV-A71 season, and sampling time after symptom onset were significantly associated with the diagnostic performance of this anti-EV-A71 IgM-capture ELISA.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusion</h3><p>Achieving satisfactory specificity and sensitivity scores, this commercial anti-EV-A71 IgM-capture ELISA kit is suitable for clinical EV-A71 diagnosis, particularly in resource-poor areas. However, clinicians should interpret results in the context of patient history and epidemiological setting.</p>
virology